Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: The OCEANS study

American Journal of Cardiovascular Drugs

Volumn 8, Issue 2, 2008, Pages 69-81

  Karas, Richard H ^a   Kashyap, Moti L ^b   Knopp, Robert H ^c   Keller, Laurence H ^d   Bajorunas, Daiva R ^d   Davidson, Michael H ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d ABBOTT LABORATORIES   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antihyperlipidaemics, therapeutic use; HMG CoA reductase inhibitors, therapeutic use; Hypercholesterolaemia, treatment; Hyperlipidaemia, treatment; Lipid metabolism disorders, treatment; Niacin, therapeutic use; Simvastatin, pharmacodynamics

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID PLUS SIMVASTATIN; SIMCOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; FIBROMYALGIA; FLUSHING; GOUT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; FLUSHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NIACIN; SIMVASTATIN; TRIGLYCERIDES;

EID: 41049092899     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808020-00001     Document Type: Article

References (28)

1. LaRosa JC, Jiang H, Suma V. Effect of statins on risk of coronary disease: a metaanalysis of randomized controlled trials. JAMA 1999; 24: 2340-6
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
5. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110 (2): 227-39
6. Hsia SH. Non-HDL cholesterol: into the spotlight. Diabetes Care 2003; 26 (1): 240-2
7. Brown GB, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a metaanalysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17: 631-6
8. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) program evaluation project utilizing novel e-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol 2005; 96: 556-63
9. Evaluation of the safety & efficacy of a combination of niacin ER & simvastatin in patients with dyslipidemia (OCEANS) [ClinicalTrials.gov identifier: NCT00080275]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00080275 [Accessed 2008 Feb 28]
10. Allain CC, Poon L, Chan SG, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5
11. Cole TG, Ferguson CA, Gibson DW, et al. Optimization of β-quantification methods for high-throughput applications. Clin Chem 2001; 47: 712-21
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the ultracentrifuge. Clin Chem 1972; 18: 449-502
13. Kohlmeier M. Direct enzymic measurement of glycerides in serum and in lipo-protein fractions. Clin Chem 1986; 32: 63-6
14. 2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-88
15. Autokit Apo A-1: code no. 991-27201 [product insert]. Rev. #1/9603IBD002K. Osaka: WakoPure Chemical Industries, Ltd; 1996
16. Autokit Apo B: code no. 993-27401 [product insert]. Rev. #1/9603IBD002K. Osaka: WakoPure Chemical Industries, Ltd; 1996
17. Autokit Lp(a): code no. 995-41901 [product insert]. Rev. #1/9903IBD00K. Osaka: WakoPure Chemical Industries, Ltd; 1999
18. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345 (22): 1583-92
19. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7
20. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22: 2243-50
21. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192 (2): 432-7
22. Rubenfire M, for the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) Study Group. Am J Cardiol 2004; 94: 306-11
23. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264: 723-6
24. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284 (10): 1263-70
25. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002; 162: 1568-76
26. Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006; 4 (4): 461-76
27. Karas R, Cziraky M, Quimbo R, et al. Cardiovascular event reduction associated with achieving optimal values multiple lipids [abstract]. Circulation 2006; 114 Suppl. II: 898
28. Niacin plus statin to prevent vascular events [ClinicalTrials.gov identifier: NCT00120289]. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00120289 [Accessed 2008 Feb 28]